Abstract 3898
Background
Integration of oncology and palliative care (PC) combines two paradigms: the tumour-directed approach, which is the main focus of oncology, and the host-directed approach, which is the focus of PC. Contemporary PC aims to prevent, treat and reduce symptoms and suffering and to preserve and improve quality of life. A Lancet Oncology Commission was written on how PC and oncology can be integrated by combining these two approaches focusing content, models, organization of cancer care, public health, politics, education and research.
Methods
An international panel was established, consisting of experts in oncology, PC, public health and psycho-oncology. Literature searches were conducted, author meetings were held, and an interactive writing process was conducted.
Results
Integration is a complex process that involves various components of the health care system. The published RCTs on integration demonstrate health gains, but how and when to integrate is uncertain. Still, early delivery of specialist palliative care promotes patient-centeredness including shared-decision making, family involvement and regular use of patient-reported outcome measures. Barriers to integration include the perception of PC as end-of-life care, deficient planning at local, national and international levels, and insufficient infrastructure and funding. Furthermore, death and dying are stigmatized. The present competence in combined oncology and PC varies substantially and must be defined at all levels. The commission proposes to use standardized care pathways (SCPs) and multidisciplinary teams (MDTs) to promote integration. Integration raises new research questions: how much, when and how should PC be delivered and what is the minimum model for good care?
Conclusions
Integration involves the transition from a dualistic perspective - the tumor and the host- to a combined perspective. Integration must be recommended by health care authorities and decision-takers, followed by resource allocation and priority-setting. In all areas, the present volume of PC is too small to support integration on a broad scale. Implementation of integrated models is best secured by MDTs and SCPs. The combined perspective must be reflected in care models, education and research funding.
Clinical trial identification
Legal entity responsible for the study
Oslo University Hospital.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
S. Kaasa, J.H. Loge: Stockholder: Eir-solution. T. Albreht: Grants: European Commission and Ministry of Health of Slovenia, during the conduct of the study; Grants and personal fees: Pfizer Oncology, outside the submitted work. A.T. Caraceni: Grants: Molteni; Grants and personal fees: Italfarmaco; Personal fees: Sandoz, Pierre Fabre Institute; Gants: Gruenenthal, Ipsen, outside the submitted work. K. Jordan: Personal fees: MSD, Helsinn, Tesaro, Amgen, Pfizer, Merck, Hexal, outside the submitted work. All other authors have declared no conflicts of interest.
Resources from the same session
4942 - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer
Presenter: Tony Loughman
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5641 - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at diagnosis with their older counterparts.
Presenter: Guek Eng Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4448 - TNBC universe: a monocentric retrospective analyses of TILs and AR as prognostic markers
Presenter: Agnese Losurdo
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4755 - Genomic spectrum of Asian breast cancer based on targeted next-generation sequencing in 150 consecutive primary breast cancer
Presenter: Chihwan Cha
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2741 - The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)
Presenter: Anees Hassan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3356 - Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases
Presenter: Da Young Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4020 - Genetic Alterations of Early-Stage Breast Cancers by next-generation sequencing (NGS)
Presenter: Yan Xu
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4924 - Oncotype Dx results in patients _40 years, Does age matters?: new insights
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2646 - Impact of BRCA status on outcomes and survival in high-risk early breast cancers
Presenter: Elodie Klajer
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4516 - Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy
Presenter: Nawale Hajjaji
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract